Mitigating risk in the development of clinical antibodies

There is considerable financial risk involved in the commercial development of new drugs, and given the massive investment in time, resources and money needed to bring a drug to market, even a modest reduction in that risk can equate to significant savings.

The development of therapeutic antibodies has been experiencing something of a boom over the last decade, and antibodies currently make up the majority of the best-selling drugs on the market. In 2018 for example, 8 of the 10 best-selling drugs on the market were antibodies. Therapeutic antibodies do sidestep some of the challenges that face the developers of chemical drugs, but this does not mean that the commercial development of therapeutic antibodies is without its own risks.

In this recent article on The Digital Biologist, Gordon highlights some of the approaches that we use at Amber Biology, to identify and mitigate potential development risks in the antibodies that are clients are working to bring to the clinic.

Bioinformatics, Biomedical Research, Business, Immunotherapy, Protein Engineering, Structural BiologyGordon WebsterJune 8, 2021antibodies, protein engineering, structural biology, bioinformatics, immunology, immunotherapy